Cookies

Like most websites The Medicine Maker uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Discovery & Development Drug Delivery, Formulation

Breathe It In

Historically, inhaled drugs have targeted the main respiratory diseases, namely asthma and chronic obstructive pulmonary disease. Inhaled drug delivery, however, has a number of inherent advantages that can also benefit other therapeutic areas. Compared with oral drugs, for example, inhaled medicines avoid first-pass metabolism and degradation in the GI tract. Inhaled drugs also often require lower dose levels and usually provide faster onset of action (1). And when it comes to comparison with parenterals, inhaled drugs are less intrusive and provide improved stability, especially for proteins and peptides (2).

Read the full article now

Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!

Login

Or register now - it’s free and always will be!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine
Register

Or Login via Social Media

By clicking on any of the above social media links, you are agreeing to our Privacy Notice.

About the Author

Simon Moore

Simon Moore is Director of Inhalation Science and Engineering at Envigo, UK.

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register